Clinical trials: Oesophageal Cancer Metastatic
Advanced Oesophageal Squamous Cell Carcinoma
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard…
- Trial name
- NCT06656091
- Testing
- simmitinib, investigator's choice of chemotherapy,include docetaxel or irinotecan.
- Volunteers
- 450 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Esophageal Neoplasms, Lymph Node Metastases
Distribution of Lymph Node Metastases in Esophageal Carcinoma
Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival.
- Trial name
- TIGER (NCT03222895)
- Where
- 19 sites in United States, Brazil and 12 more
- Volunteers
- 5,000 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Solid Tumor, Advanced Cancer
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
- Trial name
- NCT04900818
- Testing
- TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy
- Where
- 21 sites in United States, China
- Volunteers
- 330 people
- Sponsor
- I-Mab Biopharma US Limited
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Stomach Neoplasms, Cancer of Stomach
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
The purpose of this study is to determine whether ASLAN001 has an effect in patients with recurrent or metastatic adenocarcinoma of the stomach, gastrooesophageal junction, or lower third of the oesophagus whose tumours…
- Conditions
- Stomach Neoplasms, Cancer of Stomach, Cancer of the Stomach, Gastric Cancer
- Trial name
- NCT01614522
- Testing
- ASLAN001
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- ASLAN Pharmaceuticals
Gastrointestinal Tumor
Phase I Trial of Combination of FOLFIRI and SOM 230
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and FOLFIRI. We will utilize a sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 when combined with…
- Trial name
- NCT01434069
- Testing
- SOM230C LAR, FOLFIRI Infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
Metastatic Spinal Cord Compression, Radiation Toxicity
Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression.
Metastatic spinal cord compression (MSCC) is a serious complication to metastatic cancer and when diagnosed life expectancy is short. Treatment is palliative radiotherapy (RT).
- Conditions
- Metastatic Spinal Cord Compression, Radiation Toxicity, Esophagitis, Patient Reported Outcome Measures
- Trial name
- ESO-SPARE (NCT05109819)
- Testing
- Esophagus sparring radiotherapy treatment
- Where
- 2 sites in Denmark
- Volunteers
- 200 people
- Sponsor
- Herlev Hospital
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma
Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC). However, the station-specific distribution of residual lymph node metastasis after NCIT remains…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis
- Trial name
- NCT07902544
- Volunteers
- 717 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic).
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- NCT04221893
- Testing
- Radiation Therapy (RT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Metastatic Esophageal Squamous Cell Carcinoma
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Trial name
- REICRAE (NCT06190652)
- Testing
- Chemotherapy combined with immunotherapy, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 728 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a…
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8
- Trial name
- NCT04248452
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- 453 sites in United States
- Volunteers
- 314 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Advanced Esophageal Carcinoma
FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma
This phase Ⅱ study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.
- Trial name
- NCT02023593
- Testing
- FOLFIRI
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yuhong Li
Esophageal Cancer
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
Capecitabine is an orally administered fluoropyrimidine that is converted by 5-FU by thymidine phosphorylase (TP), preferentially in tumor tissues and has demonstrated activity as single agent in patients with gastrointestinal…
- Trial name
- NCT00453323
- Testing
- Paclitaxel, Capecitabine
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- National Cancer Center, Korea
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or…
- Trial name
- NCT07621601
- Testing
- HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel
- Volunteers
- 494 people
- Sponsor
- Hansoh BioMedical R&D Company
Neuroendocrine Carcinoma
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and…
- Trial name
- NCT03168594
- Testing
- irinotecan cisplatin, Etoposide cisplatin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer
Futibatinib in Patients With Specific FGFR Aberrations
The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts.
- Conditions
- Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
- Trial name
- NCT04189445
- Testing
- Futibatinib
- Where
- 61 sites in United States, Belgium and 13 more
- Volunteers
- 115 people
- Sponsor
- Taiho Oncology, Inc.